TW200803895A - Method of using IL6 antagonists with proteasome inhibitors - Google Patents

Method of using IL6 antagonists with proteasome inhibitors Download PDF

Info

Publication number
TW200803895A
TW200803895A TW095145881A TW95145881A TW200803895A TW 200803895 A TW200803895 A TW 200803895A TW 095145881 A TW095145881 A TW 095145881A TW 95145881 A TW95145881 A TW 95145881A TW 200803895 A TW200803895 A TW 200803895A
Authority
TW
Taiwan
Prior art keywords
antibody
pharmaceutical composition
disease
cells
proteasome
Prior art date
Application number
TW095145881A
Other languages
English (en)
Chinese (zh)
Inventor
Mohamed H Zaki
Jeffrey A Nemeth
Robert Z Orlowski
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of TW200803895A publication Critical patent/TW200803895A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW095145881A 2005-12-09 2006-12-08 Method of using IL6 antagonists with proteasome inhibitors TW200803895A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74915205P 2005-12-09 2005-12-09

Publications (1)

Publication Number Publication Date
TW200803895A true TW200803895A (en) 2008-01-16

Family

ID=38123650

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095145881A TW200803895A (en) 2005-12-09 2006-12-08 Method of using IL6 antagonists with proteasome inhibitors

Country Status (15)

Country Link
US (1) US20090022726A1 (https=)
EP (1) EP1954310A4 (https=)
JP (1) JP2009518447A (https=)
KR (1) KR20080072761A (https=)
CN (1) CN101325969A (https=)
AR (1) AR057227A1 (https=)
AU (1) AU2006321610A1 (https=)
BR (1) BRPI0619498A2 (https=)
CA (1) CA2632732A1 (https=)
EA (1) EA014675B1 (https=)
IL (1) IL191694A0 (https=)
NO (1) NO20082907L (https=)
TW (1) TW200803895A (https=)
WO (1) WO2007067976A2 (https=)
ZA (1) ZA200805956B (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8771686B2 (en) 2006-01-27 2014-07-08 Chugai Seiyaku Kabushiki Kaisha Methods for treating a disease involving choroidal neovascularization by administering an IL-6 receptor antibody
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
US9260516B2 (en) 2006-04-07 2016-02-16 Osaka University Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
US9539322B2 (en) 2010-05-28 2017-01-10 National University Corporation Hokkaido University Method of enhancing an antitumor T cell response by administering an anti-IL-6 receptor antibody
US9725514B2 (en) 2007-01-23 2017-08-08 Shinshu University Chronic rejection inhibitor
US10717781B2 (en) 2008-06-05 2020-07-21 National Cancer Center Neuroinvasion inhibitor
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US12600772B2 (en) 2018-01-31 2026-04-14 Motokazu Kato Therapeutic agent for asthma containing IL-6 inhibitor

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129346B2 (en) 2004-04-15 2012-03-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
EP2030981B1 (en) 2004-05-10 2014-07-09 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
MY171061A (en) 2005-11-09 2019-09-24 Onyx Therapeutics Inc Compounds for enzyme inhibition
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
CA2657213C (en) 2006-06-19 2017-01-03 Proteolix, Inc. Peptide epoxyketones for proteasome inhibition
EP2174667B1 (en) * 2007-07-26 2017-01-04 Osaka University Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
KR20170125413A (ko) 2007-10-04 2017-11-14 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
EA201170527A1 (ru) * 2008-10-01 2011-10-31 Др. Редди'С Лабораторис Лтд. Фармацевтические композиции, включающие соединения бороновой кислоты
EP3090737A1 (en) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
KR20160091440A (ko) * 2008-11-13 2016-08-02 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
WO2011006273A1 (en) 2009-07-15 2011-01-20 Eva Kovacs-Benke Combination of a human interleukin-6 antagonist and a human interleukin-6 receptor antagonist in therapy of tumour diseases
WO2011013786A1 (ja) * 2009-07-31 2011-02-03 Maeda Shin 癌の転移抑制剤
US7947653B1 (en) 2009-10-09 2011-05-24 Cold Spring Harbor Laboratory Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers
US8323883B1 (en) 2009-10-09 2012-12-04 Cold Spring Harbor Laboratory Methods of assessing therapeutic benefits of patients having cancers resistant to epidermal growth factor receptor kinase inhibitors
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
EP2542238B1 (en) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
US20140294854A1 (en) * 2011-03-10 2014-10-02 Albert Einstein College Of Medicine Of Yeshiva University Target directed to adipocytes, methods and assays for treatment of obesity
WO2013175276A1 (en) * 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
KR101643041B1 (ko) * 2014-04-25 2016-07-28 아주대학교산학협력단 프로테아좀 저해제 및 디히드로피리딘계 화합물을 유효성분으로 함유하는 암의 예방 또는 치료용 조성물
CN108030916A (zh) * 2015-07-03 2018-05-15 刘永庆 防治肿瘤和/或慢性结核病的Th2免疫反应抑制剂及其应用
WO2017138008A2 (en) * 2016-02-14 2017-08-17 Yeda Research And Development Co. Ltd. Methods of modulating protein exocytosis and uses of same in therapy
US20200246488A1 (en) * 2017-07-17 2020-08-06 The Broad Institute, Inc. Compositions and methods for treating inflammatory bowel diseases
US20200165608A1 (en) * 2018-11-23 2020-05-28 Florida State University Research Foundation, Inc. Inhibition of vascular endothelial cell-mediated phagocytic processes for treatment of demyelinating conditions
EP3957324A4 (en) 2019-04-17 2023-02-08 Hiroshima University THERAPEUTIC FOR UROLOGICAL ONCOLOGY CHARACTERIZED BY BEING ADMINISTRATED IN COMBINATION WITH IL-6 INHIBITOR AND CCR2 INHIBITOR

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210075A (en) * 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
US5340736A (en) * 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
AU6808194A (en) * 1993-05-31 1994-12-20 Chugai Seiyaku Kabushiki Kaisha Reconstructed human antibody against human interleukin-6
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
KR20010080267A (ko) * 1998-10-20 2001-08-22 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아솜 억제제 약물 작용을 모니터링하는 방법
PT2308888T (pt) * 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
WO2004071404A2 (en) * 2003-02-04 2004-08-26 Centocor Inc. Use of il-6 antagonists in combination with steroids to enhance apoptosis
JO3058B1 (ar) * 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
US8771686B2 (en) 2006-01-27 2014-07-08 Chugai Seiyaku Kabushiki Kaisha Methods for treating a disease involving choroidal neovascularization by administering an IL-6 receptor antibody
US9260516B2 (en) 2006-04-07 2016-02-16 Osaka University Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
US9725514B2 (en) 2007-01-23 2017-08-08 Shinshu University Chronic rejection inhibitor
US10717781B2 (en) 2008-06-05 2020-07-21 National Cancer Center Neuroinvasion inhibitor
US9539322B2 (en) 2010-05-28 2017-01-10 National University Corporation Hokkaido University Method of enhancing an antitumor T cell response by administering an anti-IL-6 receptor antibody
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US12509511B2 (en) 2017-05-02 2025-12-30 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
US12600772B2 (en) 2018-01-31 2026-04-14 Motokazu Kato Therapeutic agent for asthma containing IL-6 inhibitor

Also Published As

Publication number Publication date
EP1954310A2 (en) 2008-08-13
CA2632732A1 (en) 2007-06-14
US20090022726A1 (en) 2009-01-22
AR057227A1 (es) 2007-11-21
EA200870029A1 (ru) 2008-10-30
KR20080072761A (ko) 2008-08-06
ZA200805956B (en) 2009-10-28
IL191694A0 (en) 2008-12-29
AU2006321610A1 (en) 2007-06-14
EP1954310A4 (en) 2009-04-22
JP2009518447A (ja) 2009-05-07
WO2007067976A3 (en) 2008-02-14
EA014675B1 (ru) 2010-12-30
CN101325969A (zh) 2008-12-17
NO20082907L (no) 2008-08-26
WO2007067976A2 (en) 2007-06-14
BRPI0619498A2 (pt) 2011-10-04

Similar Documents

Publication Publication Date Title
TW200803895A (en) Method of using IL6 antagonists with proteasome inhibitors
AU2010202813B2 (en) Anti- MCP-1 antibodies, compositions, methods and uses
AU2001295490B2 (en) Antibodies to human IL-1beta
TWI547502B (zh) 用以提升白蛋白及／或降低ｃ反應性蛋白（ｃｒｐ）之ｉｌ-６拮抗劑
US9394362B2 (en) IL-21 antibodies and methods of making or using the antibodies
KR101314880B1 (ko) 관절류머티즘 치료제
AU2001295490A1 (en) Antibodies to human IL-1beta
US20140178332A1 (en) IL-12/p40 BINDING PROTEINS
WO2014100014A1 (en) Super-2 complexes with antibody to augment il-2 therapy
JP6469012B2 (ja) インターロイキン−６に対する抗体およびその使用
EP2182943B1 (en) Methods and compositions for treating fibrosis related disorders using il-17 antagonists
JP2019534282A (ja) 抗ｉｌ−３３抗体およびその使用
TW200302107A (en) Combination of an IL-1/18 inhibitor with a TN F inhibitor for the treatment of inflammation
EP2729174A1 (en) Il-23 antagonists for treatment or prevention of skin rash associated with treatment with p13k/akt pathway inhibitors
US20100254992A1 (en) Anti-mcp-1 antibodies, compositions, methods and uses
CN116635422A (zh) 抗cd38抗体及其用途
KR101453516B1 (ko) 항-ｖｅｇｆ 항체를 포함하는 자가면역질환 예방 및 치료용 조성물
HK40099176A (zh) 抗cd38抗体及其用途
HK40105127B (zh) 抗cd40抗体
HK40105127A (zh) 抗cd40抗体
JP2010116338A (ja) 同一抗原に特異的に結合する複数の抗体の混合物もしくは複数の抗原結合部位を有する抗体
WO2007146857A2 (en) Anti- mcp-1 antibodies expressed in lemna, compositions, methods and uses
MX2008007329A (en) Method of using il6 antagonists with proteasome inhibitors